BCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
BioCryst Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2024 was $12.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was $-45.3 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BioCryst Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2024 was 37.36%. BioCryst Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 631.52%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. BioCryst Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -2.03%.
The historical data trend for BioCryst Pharmaceuticals's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBIT | Get a 7-Day Free Trial | -97.01 | -168.31 | -122.52 | -145.29 | -117.99 |
BioCryst Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
EBIT | Get a 7-Day Free Trial | -45.67 | -8.47 | -38.58 | -10.51 | 12.23 |
For the Biotechnology subindustry, BioCryst Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals (NAS:BCRX) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
BioCryst Pharmaceuticals's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:
ROC % (Q: Jun. 2024 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Mar. 2024 ) | + | Invested Capital (Q: Jun. 2024 )) | / count ) |
= | 35.044 * ( 1 - -1.38% ) | / | ( (49.554 | + | 140.643) | / 2 ) |
= | 35.5276072 | / | 95.0985 | |||
= | 37.36 % |
where
Invested Capital | (Q: Mar. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 467.892 | - | 91.159 | - | ( 336.554 | - | max(0, 119.921 | - | 447.1 | + | 336.554 | )) |
= | 49.554 |
Invested Capital | (Q: Jun. 2024 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 472.419 | - | 97.384 | - | ( 272.027 | - | max(0, 129.065 | - | 363.457 | + | 272.027 | )) |
= | 140.643 |
Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.
2. Joel Greenblatt's definition of Return on Capital:
BioCryst Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:
ROC (Joel Greenblatt) % | (Q: Jun. 2024 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Mar. 2024 | Q: Jun. 2024 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | 48.924 | / | ( ( (7.831 + max(-6.6349999999999, 0)) | + | (7.663 + max(-34.928, 0)) ) | / | 2 ) |
= | 48.924 | / | ( ( 7.831 | + | 7.663 ) | / | 2 ) |
= | 48.924 | / | 7.747 | ||||
= | 631.52 % |
where Working Capital is:
Working Capital | (Q: Mar. 2024 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (60.586 | + | 29.781 | + | 20.179) | - | (91.159 | + | 0 | + | 26.022) |
= | -6.6349999999999 |
Working Capital | (Q: Jun. 2024 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (68.759 | + | 4.45 | + | 18.221) | - | (97.384 | + | 0 | + | 28.974) |
= | -34.928 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
BioCryst Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Jun. 2024 ) |
= | -45.33 | / | 2237.829 | |
= | -2.03 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Machelle Sanders | director | C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560 |
Nancy J Hutson | director | 64 MONTAUK AVENUE, STONINGTON CT 06378 |
Helen M. Thackray | director | C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
Jon P Stonehouse | director, officer: CEO | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
Charles K Gayer | officer: Vice President and CCO | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Michael L Jones | officer: Exec Director, Finance - PAO | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Alane P Barnes | officer: VP, General Counsel & Corp Sec | 1929 BRASSFIELD ROAD, RALEIGH NC 27614 |
Anthony Doyle | officer: Chief Financial Officer | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Yarlagadda S Babu | officer: VP Drug Discovery | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
George B Abercrombie | director | C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
William P Sheridan | officer: SR VP - CMO | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
Vincent Milano | director | C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341 |
Amy E Mckee | director | 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703 |
Lee Kenneth B Jr | director | 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4 |
Steven K Galson | director | C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703 |
From GuruFocus
By Marketwired • 08-23-2023
By Marketwired • 07-17-2023
By Marketwired • 07-19-2023
By PRNewswire PRNewswire • 05-03-2023
By sperokesalga sperokesalga • 04-27-2023
By sperokesalga sperokesalga • 06-06-2023
By sperokesalga sperokesalga • 02-22-2023
By sperokesalga sperokesalga • 05-31-2023
By Marketwired • 07-06-2023
By sperokesalga sperokesalga • 03-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.